NervGen Pharma Corp
XTSX:NGEN

Watchlist Manager
NervGen Pharma Corp Logo
NervGen Pharma Corp
XTSX:NGEN
Watchlist
Price: 6.85 CAD -4.06% Market Closed
Market Cap: CA$503.9m

Relative Value

There is not enough data to reliably calculate the relative value of NGEN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NGEN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

NGEN Competitors Multiples
NervGen Pharma Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
NervGen Pharma Corp
XTSX:NGEN
524.1m CAD 0 -20.3 -19.3 -19.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
US
Johnson & Johnson
NYSE:JNJ
529.7B USD 5.6 19.8 13.8 16.9
CH
Roche Holding AG
SIX:ROG
277.3B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP 4.9 30.4 19.8 29
CH
Novartis AG
SIX:NOVN
222B CHF 5 19.5 15.6 20.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.1 11.9 13.8
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.8B USD 2.3 14.8 7.5 10.3
FR
Sanofi SA
PAR:SAN
96.9B EUR 1.5 7.1 6.4 6.4
P/S Multiple
Revenue Growth P/S to Growth
CA
NervGen Pharma Corp
XTSX:NGEN
Average P/S: 14.5
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
16.9
27%
0.6
US
Johnson & Johnson
NYSE:JNJ
5.6
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.5
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
4.9
8%
0.6
CH
Novartis AG
SIX:NOVN
5
5%
1
DK
Novo Nordisk A/S
CSE:NOVO B
5.6
5%
1.1
US
Merck & Co Inc
NYSE:MRK
4.2
4%
1
IE
E
Endo International PLC
LSE:0Y5F
94
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
FR
Sanofi SA
PAR:SAN
1.5
5%
0.3
P/E Multiple
Earnings Growth PEG
CA
NervGen Pharma Corp
XTSX:NGEN
Average P/E: 23
Negative Multiple: -20.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
17.1
2%
8.6
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
FR
Sanofi SA
PAR:SAN
7.1
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
NervGen Pharma Corp
XTSX:NGEN
Average EV/EBITDA: 47.9
Negative Multiple: -19.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.8
10%
2
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
NervGen Pharma Corp
XTSX:NGEN
Average EV/EBIT: 102.7
Negative Multiple: -19.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
16.9
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29
23%
1.3
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4